ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 141 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2022. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $198,925 | +4.1% | 202,985 | +394.4% | 0.00% | – |
| Q1 2022 | $191,000 | -43.8% | 41,059 | +281.1% | 0.00% | -100.0% |
| Q1 2020 | $340,000 | +49.1% | 10,774 | +73.3% | 0.00% | – |
| Q3 2019 | $228,000 | -49.1% | 6,216 | -45.7% | 0.00% | – |
| Q2 2018 | $448,000 | -90.2% | 11,442 | -81.9% | 0.00% | -100.0% |
| Q1 2018 | $4,581,000 | +174.1% | 63,336 | +149.6% | 0.01% | +150.0% |
| Q4 2017 | $1,671,000 | -67.9% | 25,380 | -75.5% | 0.00% | -66.7% |
| Q3 2017 | $5,199,000 | +282.0% | 103,726 | +252.7% | 0.01% | +200.0% |
| Q2 2017 | $1,361,000 | -4.1% | 29,407 | -51.1% | 0.00% | -33.3% |
| Q3 2015 | $1,419,000 | -77.3% | 60,167 | -21.1% | 0.00% | -75.0% |
| Q2 2015 | $6,238,000 | -0.9% | 76,296 | +12.2% | 0.01% | -14.3% |
| Q1 2015 | $6,297,000 | +1187.7% | 68,000 | +462.0% | 0.01% | +1300.0% |
| Q4 2014 | $489,000 | – | 12,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |